Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease.
about
Inhibitors of connexin and pannexin channels as potential therapeutics.Purinergic Signalling: Therapeutic Developments.Modulation of the main porcine enteric neuropeptides by a single low-dose of lipopolysaccharide (LPS) Salmonella Enteritidis.The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression.The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?
P2860
Inhibiting purinergic P2X7 receptors with the antagonist brilliant blue G is neuroprotective in an intranigral lipopolysaccharide animal model of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibiting purinergic P2X7 rec ...... model of Parkinson's disease.
@en
Inhibiting purinergic P2X7 rec ...... model of Parkinson's disease.
@nl
type
label
Inhibiting purinergic P2X7 rec ...... model of Parkinson's disease.
@en
Inhibiting purinergic P2X7 rec ...... model of Parkinson's disease.
@nl
prefLabel
Inhibiting purinergic P2X7 rec ...... model of Parkinson's disease.
@en
Inhibiting purinergic P2X7 rec ...... model of Parkinson's disease.
@nl
P2093
P2860
P356
P1476
Inhibiting purinergic P2X7 rec ...... model of Parkinson's disease.
@en
P2093
Hong Shang
Xin-Hong Wang
P2860
P304
P356
10.3892/MMR.2016.6070
P577
2016-12-23T00:00:00Z